The Michael Mason prize: Pathogenic antiphospholipid antibodies, stressed out antigens and the deployment of decoys

Rheumatology

Volumn 51, Issue 1, 2012, Pages 32-36

  Ioannou, Yiannis ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

2 glycoprotein I; Antiphospholipid antibodies; Antiphospholipid syndrome

Indexed keywords

ARGININE; BETA2 GLYCOPROTEIN 1; IMMUNOGLOBULIN G; PHOSPHOLIPID ANTIBODY;

ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; CELL ACTIVATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN STRUCTURE; REVIEW; THROMBOGENESIS;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AWARDS AND PRIZES; BETA 2-GLYCOPROTEIN I; HISTORY, 21ST CENTURY; HUMANS; IMMUNODOMINANT EPITOPES; MICE; OXIDATION-REDUCTION; RECOMBINANT PROTEINS; RHEUMATOLOGY;

EID: 84855165588     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker353     Document Type: Review

References (37)

1. Derksen RH, de Groot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993;52:689-92.
2. Khamashta MA, Cuadrado MJ, Mujic F et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-7.
3. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007;57: 1487-95.
4. Pengo V, Ruffatti A, Legnani C et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010;8:237-42.
5. Pierangeli SS, Liu SW, Anderson G et al. Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation 1996;94:1746-51.
6. Pierangeli SS, Liu X, Espinola R et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000;84:388-95.
7. Raschi E, Testoni C, Bosisio D et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003;101:3495-500.
8. Pierangeli SS, Colden-Stanfield M, Liu X et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999;99:1997-2002.
9. Opara R, Robbins DL, Ziboh VA. Cyclic-AMP agonists inhibit antiphospholipid/beta2-glycoprotein I induced synthesis of human platelet thromboxane A2 in vitro. J Rheumatol 2003;30:55-9.
10. Shi T, Giannakopoulos B, Yan X et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006;54:2558-67.
11. Atsumi T, Ieko M, Bertolaccini ML et al. Association of autoantibodies against the phosphatidylserineprothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000;43:1982-93.
12. Oosting JD, Derksen RH, Bobbink IW et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993;81:2618-25.
13. Pengo V, Biasiolo A, Brocco T et al. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996;75:721-4.
14. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2- glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4.
15. Galli M, Comfurius P, Maassen C et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
16. Matsuura E, Igarashi Y, Fujimoto M et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;336:177-8.
17. Miyakis S, Giannakopoulos B, Krilis SA. Beta 2 glycoprotein I-function in health and disease. Thromb Res 2004; 114:335-46.
18. Schwarzenbacher R, Zeth K, Diederichs K et al. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999;18:6228-39.
19. Bouma B, de Groot PG, van den Elsen JM et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999;18: 5166-74.
20. Schmidt B, Ho L, Hogg PJ. Allosteric disulfide bonds. Biochemistry 2006;45:7429-33.
21. Chen VM, Hogg PJ. Allosteric disulfide bonds in thrombosis and thrombolysis. J Thromb Haemost 2006;4:2533-41.
22. Chen VM, Ahamed J, Versteeg HH et al. Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry 2006;45:12020-8.
23. Ahamed J, Versteeg HH, Kerver M et al. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci USA 2006;103:13932-7.
24. Ioannou Y, Zhang JY, Passam FH et al. Naturally occurring free thiols within {beta}2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells and regulation of oxidative stress induced cell injury. Blood 2010;116: 1961-70.
25. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
26. Ioannou Y, Zhang JY, Qi M et al. Novel assays of thrombogenic pathogenicity for the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen ss2-glycoprotein I. Arthritis Rheum 2011;63:2774-82.
27. Ioannou Y, Zhang JY, Qi M et al. ß2-glycoprotein I exists in a distinct molecular post-translational oxidative state in the antiphospholipid syndrome: novel prognostic assays and insights in antigenicity. Arthritis Rheum 2010;62:S259 (Plenary Abstract 612).
28. Agar C, van Os GM, Morgelin M et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010;116:1336-43.
29. Reddel SW, Wang YX, Sheng YH, Krilis SA. Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun 2000;15: 91-6.
30. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA 1998;95:15542-6.
31. de Laat B, Derksen RH, van Lummel M et al. Pathogenic anti-{beta}2-glycoprotein I antibodies recognize domain I of {beta}2-glycoprotein I only after a conformational change. Blood 2006;107:1916-24.
32. Ioannou Y, Pericleous C, Giles I et al. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007;56: 280-90.
33. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007;109:422-30.
34. Ioannou Y, Giles I, Lambrianides A et al. A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. BMC Biotechnol 2006;6:8.
35. Ioannou Y, Romay-Penabad Z, Pericleous C et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost 2009;7:833-42.
36. Pericleous C, Ioannou Y. New therapeutic targets for the antiphospholipid syndrome. Expert Opin Ther Targets 2010;14:1291-9.
37. Ioannou Y, Rahman A. Domain I of beta2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome. Lupus 2010;19:400-5.